Drug-induced liver injury throughout the drug development life cycle: Where we have been, where we are now, and where we are headed. Perspectives of a clinical hepatologist

Pharmaceutical Medicine

Volumn 27, Issue 3, 2013, Pages 165-191

  Lewis, James H ^a,b  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BROMFENAC; LIVER ENZYME; TROGLITAZONE;

ADAPTATION; ADVISORY COMMITTEE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTATIC HEPATITIS; DRUG DEVELOPMENT; DRUG MONITORING; DRUG SAFETY; DRUG TOLERANCE; FOOD AND DRUG ADMINISTRATION; HOST SUSCEPTIBILITY; HUMAN; KAPLAN MEIER METHOD; LIFE CYCLE; LIVER NECROSIS; LIVER TOXICITY; NONHUMAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; TOXIC HEPATITIS;

EID: 84878528772     PISSN: 11782595     EISSN: 11791993     Source Type: Journal    
DOI: 10.1007/s40290-013-0015-5     Document Type: Review

References (249)

1. Temple R. The drug development process. An FDA perspective. In: Friedman G, Jacobson ED, McCallum RW, editors. Gastrointestinal pharmacology and therapeutics. Philadelphia: Lippincott-Raven Publishers; 1997. p. 677-92.
2. Hutt PB. Investigations and reports respecting FDA regulations of new drugs (parts I and II). Clinical Pharmacol Ther 1983;33(4):537-48, 674-87.
3. Shulman SR, Hewitt T, Manocchioa M. Studies and inquiries into the FDA regulatory process: a historical review. Drug Inf J. 1995;29:385-413.
4. Stevens JL, Baker TK. The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov Today. 2009;14(3-4):162-7.
5. Senior JR. Drug hepatotoxicity from a regulatory perspective. Clin Liver Dis. 2007;11:507-24.
6. Committee on the Assessment of the US Drug Safety System. Baciu A, Stratton K, Burke SP, editors. The future of drug safety: promoting and protecting the health of the public. Washington, DC: The National Academies Press; 2007.
7. FDA. FDA drug development and approval process. http://www.fda.gov/drugs/ developmentapprovalprocess/default.htm. (Accessed 22 March 2013).
8. FDA. Innovation or stagnation: challenges and opportunities on the critical path to new medical products (2004). http://www.fda.gov/ ScienceResearch/SpecialTopics/CriticalPathInitiative/ CriticalPathOpportunitiesReports/ucm077262.htm (Accessed 21 March 2013).
9. Zimmerman HJ. Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999.
10. Popper H, Rubin E, Cardiol D, et al. Drug-induced liver disease: a penalty for progress. Arch Intern Med. 1965;115:128-36.
11. Schuster D, Laggner C, Langer T. Why drugs fail - a study on side effects in new chemical entities. Curr Pharm Des. 2005;11(27):3545-59.
12. Olson H. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol. 2000;32(1):56-67.
13. FDA. Liver Toxicity Knowledge Base (LTKB) http://www.fda.gov/ ScienceResearch/BioinformaticsTools/LiverToxicityKnowledgeBase/default.htm (Accessed 22 March 2013).
14. Lasser KE, Allen PD, Woolhandler SJ, et al. Timing of black box warnings and withdrawals for prescription medications. JAMA. 2002;287(17):2215-20.
15. FDA guidance exploratory studies FDA Working Group. Nonclinical assessment of potential hepatotoxicity in man. November 2000. http://www.fda.gov/downloads/drugs/scienceresearch/researchareas/ucm091453.pdf (Accessed 21 March 2013).
16. Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med. 2005;165(12):1363-9.
17. Rodriguez EM, Staffa JA, Graham DJ. The role of databases in drug postmarketing surveillance. Pharmacoepidemiol Drug Saf. 2001;10(5):407-10.
18. Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf. 2002;25(6):381-92.
19. Guidance for clinical trial sponsors on the establishment and operation of clinical trial data monitoring committees: draft guidance. Rockville: Food and Drug Administration; 2001. http://www.fda.gov/downloads/ Regulatoryinformation/Guidances/ucm127073.pdf (Accessed 21 March 2013).
20. Ahmad SR. Adverse drug event monitoring at the Food and Drug Administration. J Gen Intern Med. 2003;18(1):57-60.
21. th-year medical students. Pharmacoepidemiol Drug Saf. 2003;12(2):97-101.
22. Hartford CG, Ptechel KS, Mickail H, et al. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines. Drug Saf. 2006;29(8):657-73.
23. Cook DM, Gurugubelli RK, Bero LA. Risk management policy and black-box warnings: a qualitative analysis of US FDA proceedings. Drug Saf. 2009;32(11):1057-66.
24. Grandinetti CA, Osborne SF. The Food and Drug Administration's drug safety oversight board: an evolving paradigm for clinical input on drug safety topics. Clin Pharmacol Ther. 2010;88(2):269-74.
25. Liu Z, Shi Q, Ding D, et al. Translating clinical findings into knowledge in drug safety evaluation - drug-induced liver injury prediction system (DILIps). PLoS Comput Biol. 2011;7(12):e1002310.
26. Behrman RE, Benner JS, Brown JS, et al. Developing the sentinel system - a national resource for evidence development. N Engl J Med. 2011;364(6):498-9.
27. Platt R, Carnahan RM, Brown JS, et al. The US Food and Drug Administration's mini-sentinel program: status and direction. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):1-8.
28. Food and Drug Administration. Guidance for industry: post-marketing studies and clinical trials - implementation of section 505 (o)(3) of the federal Food, Drug, and Cosmetic Act; 2011. http://www.fda.gov/downloads/Drugs/ GuidanceComlianceRegulatoryInformation/Guidances/UCM172001.pdf (Accessed 21 March 2013).
29. Sherman RB, Woodcock J, Norden J, et al. New FDA regulation to improve safety reporting in clinical trials. N Engl J Med. 2011;365(1):3-5.
30. Morrato EH, Ling SB. The Drug Safety and Risk Management Advisory Committee: a case study of meeting frequency, content, and outcomes before and after FDAAA. Med Care. 2012;50(11):970-86.
31. Temple R. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf. 2006;15(4):241-3.
32. Graham DJ, Green L, Senior JR, et al. Troglitazone-induced liver failure: a case-study. Am J Med. 2003;114(4):299-306.
33. Faich GA, Moseley RH. Troglitazone (Rezulin) and hepatic injury. Pharmacoepidemiol Drug Saf. 2001;10(6):537-47.
34. Fontana RJ, McCashland TM, Brenner KG, et al. Acute liver failure associated with prolonged use of bromfenac leading to liver transplant. Liver Transpl Surg. 1999;5(6):480-4.
35. Goldkind L, Laine L. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Pharmacoepidemiol Drug Saf. 2006;15.
36. Tancik CA, Dillaha JA. Trovafloxacin-induced acute hepatitis. Clin Infect Dis. 2000;30(2):400.
37. FDA Working Group (Temple R, Senior JR). Clinical white paper, 2000. Conference on drug-induced liver injury: a national and global problem. Chantilly; 2001. http://www.fda.gov/cder/livertox/clinical.pdf.
38. Guidance for industry. Drug-induced liver injury: premarketing clinical evaluation. Food and Drug Administration, Silver Spring; 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM174090.pdf (Accessed 21 March 2013).
39. Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology. 2006;43(3):618-31.
40. Reuben A, Koch DG, Lee WM, et al. Drug-induced acute liver failure: results of a US multicenter, prospective study. Hepatology. 2010;52(6):2065-76.
41. Hoofnagle JH, Serrano J, Knoben JE, et al. Liver Tox. A web site on drug induced liver injury. Hepatology. 2013;57(3):873-4.
42. Lewis JH, Kleiner DE. Hepatic injury due to drugs, herbal compounds, chemicals and toxins. In: Burt AD, Portmann BC, Ferrell LD, editors. MacSween's pathology of the liver. 6th ed. Edinburgh: Churchill Livingstone/Elsevier; 2012. p. 645-760.
43. Vuppalanchi R, Liangpunsakul S, Chalasani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States? Am J Gastroenterol. 2007;102(3):558-62.
44. Mindikoglu AL, Magder LS, Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database. Liver Transpl. 2009;15(7):719-29.
45. Lee WM. Assessing causality in drug-induced liver injury. J Hepatol. 2000;33(6):1003-5.
46. Goodman Z. Drug hepatotoxicity. Clin Liver Dis. 2002;6(2):381-9.
47. Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf. 2001;24(7):483-90.
48. Kleiner DE. The pathology of drug-induced liver injury. Semin Liver Dis. 2009;29(4):364-72.
49. Zimmerman HJ. Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver. New York: Appleton-Century-Crofts; 1978.
50. Benichou C, Benhamou JP, Danan G. Consensus. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990;11(2):272-6.
51. Benichou C. Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced liver disorders: report of an international consensus meeting. Int J Clin Pharmacol Ther Toxicol. 1990;28(8):317-22.
52. Senior JR. How can "Hy's law" help the clinician? Pharmacoepidemiol Drug Saf. 2006;15(4):235-9.
53. West M, Gelb D, Pilz CG, Zimmerman HJ. Serum enzymes in disease. VII. Significance of abnormal serum enzyme levels in cardiac failure. Am J Med Sci. 1961;241:350-8.
54. West M, Heller P, Zimmerman HJ. Serum enzymes in disease. III. Lactic dehydrogenase and glutamic oxaloacetic transaminase in patients with leukemia and lymphoma. Am J Med Sci. 1958;235(6):689-701.
55. West M, Zimmerman HJ. Lactic dehydrogenase and glutamic oxaloacetic transaminase in normal pregnant women and newborn children. Am J Med Sci. 1958;235(4):443-7.
56. Korn RJ, Rock W, Zimmerman HJ. Studies of hepatic function in patients receiving promazine. Am J Med Sci. 1958;235(4):431-6.
57. Dujovne CA, Levy R, Zimmerman HJ. Hepatotoxicity of phenothiazines in vitro as measured by loss of aminotransferases to surrounding media. Proc Soc Exp Biol Med. 1968;128(2):561-3.
58. Senior JR. Monitoring for hepatotoxicity: what is the predictive value of liver 'function' tests? Clin Pharmacol Ther. 2009;85(3):331-4.
59. American Gastroenterological Association position statement: evaluation of liver chemistry tests. Gastroenterology. 2002;123(4):1364-6.
60. Green RM, Flamm S. AGA Technical review on the evaluation of liver chemistry tests. Gastroenterology. 2002;123(4):1367-84.
61. Nathwani RA, Pais S, Reynolds TB, et al. Serum alanine aminotransferase in skeletal muscle diseases. Hepatology. 2005;41(2):380-2.
62. Mohi-ud-din R, Lewis JH. Drug- and chemical-induced cholestasis. Clin Liver Dis. 2004;8(1):95-132.
63. Wolkoff AW, Berk PD. Bilirubin metabolism and jaundice. In: Schiff ER, Maddrey WC, Sorredll MF, editors. Schiff's diseases of the liver. 11th ed. New York: Wiley-Blackwell; 2012. p. 120-51.
64. Hawkins MT, Lewis JH. Latest advances in predicting DILI in human subjects: focus on biomarkers. Expert Opin Drug Metab Toxicol. 2012;8(12):1521-30.
65. Seeto RK, Fenn B, Rockey DC. Ischemic hepatitis: clinical presentation and pathogenesis. Am J Med. 2000;109(2):109-13.
66. Henrion J, Schapira M, Luwaert R, et al. Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine (Baltimore). 2003;82(6):392-406.
67. Harinasuta U, Chomet B, Ishak K, et al. Steatonecrosis - Mallory body type. Medicine (Baltimore). 1967;46(2):141-62.
68. Vuppalanchi R, Hayashi PH, Chalasani N, et al. Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network. Aliment Pharmacol Ther. 2010;32(9):1174-83.
69. Bissell DM, Gores GJ, Laskin DL, et al. Drug-induced liver injury - mechanisms and test systems. Hepatology. 2001;33(4):1009-13.
70. Kaplowitz M. Idiosyncratic drug hepatotoxicity. Nature Rev Drug Discov. 2005;4:489-9.
71. Gunawan VK, Kaplowitz N. Mechanisms of drug-induced liver disease. Clin Liver Dis. 2007;11(3):459-75.
72. Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003;349(5):474-85.
73. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354(7):731-9.
74. Trauner M, Meier PJ, Boyer JL. Molecular basis of cholestasis. N Engl J Med. 1998;339(17):1217-27.
75. Metushi IG, Cai P, Zhu X, et al. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin Pharmacol Ther. 2011;89(6):911-4.
76. Verma S, Kaplowitz N. Diagnosis, management, and prevention of drug-induced liver injury. Gut. 2009;58(11):1555-64.
77. Lewis JH. Drug-induced liver disease. Med Clin North Am. 2000;84(5):1275-311.
78. Lucena M, Andrade R, Kaplowitz N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology. 2009;49(6):2001-9.
79. Jones DP, Lemasters JJ, Han D, et al. Mechanisms of pathogenesis in drug hepatotoxicity putting the stress on mitochondria. Mol Interv. 2010;10(2):98-111.
80. Boelsterli UA, Lim PL. Mitochondrial abnormalities - a link to idiosyncratic drug hepatotoxicity? Toxicol Appl Pharmacol. 2007;220(1):92-107.
81. Uetrecht J. Role of drug metabolism for breaking tolerance and the localization of drug hypersensitivity. Toxicology. 2005;209(2):113-8.
82. Han D, Shinohara M, Ybanez MD, et al. Signal transduction pathways involved in drug-induced liver injury. Handb Exp Pharmacol. 2010;196:267-310.
83. Amacher DE. The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury. Expert Opin Drug Metab Toxicol. 2012;8(3):335-47.
84. Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Semin Liver Dis. 2009;29(4):400-11.
85. Daly AK. Drug-induced liver injury: past, present, and future. Pharmacogenomics. 2010;5:607-11.
86. Daly ASK, Day CP. Genetic association studies in drug-induced liver injury. Drug Metab Rev. 2012;44(1):116-26.
87. Uetrecht J. Immunoallergic drug-induced liver injury in humans. Semin Liver Dis. 2009;29(4):383-92.
88. Lammert C, Einarsson S, Saha C, et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology. 2008;47(6):2003-9.
89. Lammert C, Bjornsson E, Niklasson A, et al. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse effects. Hepatology. 2010;51(2):615-20.
90. Ng W, Lobach AR, Zhu X, et al. Animal models of idiosyncratic drug reactions. Adv Pharmacol. 2012;63:81-135.
91. Corsini A, Ganey P, Ju C, et al. Current challenges and controversies in drug-induced liver injury. Drug Saf. 2012;35(12):1099-117.
92. Zhang M, Chen M, Tong W. Is toxicogenomics a more reliable and sensitive biomarker than conventional indicators from rats to predict drug-induced injury in humans. Chem Res Toxicol. 2012;25(1):122-9.
93. Horsmans Y, Desager JP, Harvengt C. Biochemical changes and morphological alterations of the liver in guinea-pigs after administration of simvastatin (HMG CoA reductase-inhibitor). Pharmacol Toxicol. 1990;67(4):336-9.
94. Kornbrust DJ, MacDonald JS, Peter CP, et al. Toxicity of HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits. J Pharmacol Exp Ther. 1989;248(2):498-505.
95. Lewis JH. Clinical perspective: statins and the liver - harmful or helpful? Dig Dis Sci. 2012;57(7):1754-63.
96. Holsapple MP, Pitot HC, Cohen SH, et al. Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol Sci. 2006;89(1):51-6.
97. Uetrecht J. Role of animal models in the study of drug-induced hypersensitivity reactions. AAPS J. 2006;7(4):E914-21.
98. Dixit R, Boelsterli UA. Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodies. Drug Discov Today. 2007;12(7-8):336-42.
99. Food and Drug Administration. Guidance for Industry, Investigations and reviewers. Exploratory IND studies; 2006. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM078933.pdf (Accessed 21 March 2013).
100. Ballet F. Hepatotoxicity in drug development: detection, significance and solutions. J Hepatol. 1997;26(suppl 2):26-36.
101. Abernethy DR, Woodcock J, Lesko LJ. Pharmacological mechanism-based drug safety assessment and prediction. Clin Pharmacol Ther. 2011;89(6):793-7.
102. Ikeda T. Drug-induced idiosyncratic hepatotoxicity: prevention strategy developed after the troglitazone case. Drug Metab Pharmacokinet. 2011;26(1):60-70.
103. Amacher DE. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity. Toxicol Appl Pharmacol. 2010;245(1):134-42.
104. Cheng F, Theodorescu D, Shulman I, Lee J. In vitro transcriptomic prediction of hepatotoxicity for early drug discovery. J Theoret Biol. 2011;290:27-36.
105. O'Connell TM, Watkins PB. The application of metabonomics to predict drug-induced liver injury. Clin Pharmacol Ther. 2010;88(3):394-9.
106. Waters NJ. The role of metabonomics at the interface between drug metabolism and safety assessment. Curr Drug Metab. 2010;11(8):686-92.
107. Mandenius C, Andersson T, Alves P, et al. Toward preclinical predictive drug testing for metabolism and hepatotoxicity by using in vitro models derived from human embryonic stem cells and human cell lines - a report of the Vitrocellomics EU-project. Altern Lab Anim. 2011;39(2):147-71.
108. Van Summeren A, Renes J, van Delft J, et al. Proteomics in the search for mechanisms and biomarkers of drug-induced hepatotoxicity. Toxicol In Vitro. 2012;26(3):373-85.
109. Kia R, Sison RL, Heslop J, et al. Stem cell-derived hepatocytes as a predictive model for drug-induced liver injury: are we there yet? Br J Clin Pharmacol. 2013;75(4):885-96.
110. Low Y, Uehara T, Minowa Y, et al. Predicting drug-induced hepatotoxicity using QSAR and toxigenomics approaches. Chem Res Toxicol. 2011;24(8):1251-62.
111. Ebbels TM, Keun HC, Beckonert OP, et al. Prediction and classification of drug toxicity using probabilistic modeling of temporal metabolic data: the consortium on metabonomic toxicology screening approach. J Proteosome Res. 2007;6(11):4407-22.
112. Przybylak KR, Cronin MT. In silico models for drug-induced liver injury - current status. Expert Opin Drug Metab Toxicol. 2012;8(2):201-17.
113. McBurney RN, Hines W, Von Tungelin LS, et al. The liver toxicity biomarker study: phase design and preliminary results. Toxicol Pathol. 2009;37(1):52-64.
114. Stepan A, Walker D, Bauman J, Price D, et al. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the Unites States. Chem Res Toxicol. 2011;24(9):1345-410.
115. Kalgutkar AS, Didiuk MT. Structural alerts, reactive metabolites, and protein covalent binding: how reliable are these attributes as predictors of drug toxicity? Chem Biodivers. 2009;6(11):2115-37.
116. Gonzalbes R, Pineda-Lucena A. Small molecule databases and chemical descriptors useful in chemoinformatics: an overview. Comb Chem Throughput Screen. 2011;14(6):548.
117. Shi Q, Hong H, Senior J, et al. Biomarkers for drug-induced liver injury. Expert Rev Gastroenterol Hepatol. 2010;4(2):225-34.
118. Muller PY, Milton MN. The determination and interpretation of the therapeutic index in drug development. Nat Rev Drug Discov. 2012;11(10):751-61.
119. Valentin JP, Bialecki R, Ewart L, et al. A framework to assess the translation of safety pharmacology data to humans. J Pharmacol Toxicol Methods. 2009;60(2):152-8.
120. Watkins PB. Drug safety sciences and the bottleneck in drug development. Clin Pharmacol Ther. 2011;89(6):788-90.
121. Reuben A. Hy's law. Hepatology. 2004;39(2):574-8.
122. Davidson CS, Leevy CM, Chamberlayne EC (eds). Guidelines for evaluation of potential hepatotoxicity of drugs in clinical trials, chapter 8. In: Guidelines for detection of hepatotoxicity due to drugs and chemicals [Fogary Conference]. NIH, USA. Publication No 79-313; 1978. p. 106-18.
123. Lewis JH. 'Hy's law', 'the Rezulin Rule' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective. Pharmacoepidemiol Drug Saf. 2006;15(4):221-9.
124. Kaplowitz N. Rules and laws of drug hepatotoxicity. Pharmacoepidemiol Drug Saf. 2006;15(4):231-3.
125. Andrade RL, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512-21.
126. Bjornsson E, Olsson R. Outcome and prognostic markers to severe drug-induced liver disease. Hepatology. 2005;42(2):481-9.
127. Chalasani N, Fontana RJ, Bonjovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135(6):1924-34.
128. Devarbhavi H, Dierkhising R, Kremers W, et al. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol. 2010;105(11):2396-404.
129. Marino G, Zimmerman HJ, Lewis JH. Management of drug-induced liver disease. Curr Gastroenterol Rep. 2001;3(1):38-48.
130. Guo T, Gelperin K, Senior JR. A tool to help you decide (detect potentially serious liver injury). http://www.fda.gov/downloads/Drugs/ ScienceResearch/ResearchAreas/ucm076777.pdf (Accessed 21 March 2013).
131. Llanos L, Moreu R, Ortin T, et al. The existence of a relationship between increased serum alanine aminotransferase levels detected in premarketing clinical trials and postmarketing published hepatotoxicity case reports. Aliment Pharmacol Ther. 2010;31(12):1337-45.
132. Lee WM, Larrey D, Olsson R, et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf. 2005;28(4):351-70.
133. Andrade RJ, Lucena MI, Martin-Vivaldi R, et al. Acute liver injury associated with the use of ebrotidine, a new H2-receptor antagonist. J Hepatol. 1999;31(4):641-6.
134. Singer JB, Lewitzky S, Leroy E, et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet. 2010;42(8):711-1471.
135. Sotaxatan Thelin (sitaxentan) to be withdrawn due to cases of unpredictable serious liver injury - clinical trials are also to be stopped. http://www.ema.europa.eu/docs/en-GB/document-library/Press-release/2010/12/ WC500099707.pdf (Accessed 21 March 2013).
136. Eypasch E, Leferinga R, Kuma CK, et al. Probability of adverse events that have not yet occurred: a statistical reminder. BMJ. 1995;311:619.
137. Lin X, Parks D, Painter J, et al. Validation of multivariate outlier detection analyses used to identify potential drug-induced liver injury in clinical trial populations. Drug Saf. 2012;35(10):865-75.
138. Watkins PB, Desai M, Berkowitz SD, et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf. 2011;34(3):243-52.
139. Morris M, Lane P, Lee K, et al. An integrated analysis of liver safety data from orlistat clinical trials. Obes Facts. 2012;5(4):485-94.
140. Lewis JH. The adaptive response (drug tolerance) helps prevent drug-induced liver disease. Gastroenterol Hepatol. 2012;8(5):333-6.
141. Adams DH, Ju C, Ramaiah SK, et al. Mechanisms of immune-mediated liver injury. Toxicol Sci. 2010;115(2):307-21.
142. Bourdi M, Eiras DP, Holt MP, et al. Role of IL-6 in an IL-10 and IL-4 double knockout mouse model uniquely susceptible to acetaminophen-induced liver injury. Chem Res Toxicol. 2007;20(2):208-16.
143. Watkins PB, Zimmerman HJ, Knapp MJ, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA. 1994;271(13):992-8.
144. Watkins PB, Dube LM, Walton-Bowen K, et al. Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. Drug Saf. 2007;30(9):805-15.
145. Leaver H, Keng Lim T, Thompson P, et al. Compliance to recommended liver function monitoring in patients on statin therapy. Cardiovasc Ther. 2009;27(2):96-100.
146. Bader T. The myth of statin-induced hepatotoxicity. Am J Gastroenterol. 2010;105(5):978-80.
147. FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs. http://www.fda.gov/Drugs/DrugSafety/ ucm293101.htm (Accessed 21 March 2013).
148. Graham D, Drinkard C, Shatin D, Tsong Y, et al. Liver enzyme monitoring in patients treated with troglitazone. JAMA. 2001;286(7):831-3.
149. Okie S. Safety in numbers - monitoring risk in approved drugs. N Engl J Med. 2005;352(12):1173-6.
150. Phillips E, Mallal S. Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol Diagn Ther. 2009;13(1):1-9.
151. Gupta N, Lewis JH. Review article: The use of potentially hepatotoxic drugs in patients with liver disease. Aliment Pharmacol Ther. 2008;28(9):1021-41.
152. FDA Guidance for industry. Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. Food and Drug Administration; 2003. http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072123.pdf (Accessed 21 March 2013).
153. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. http://www.ema.europa.eu/docs/en-GB/ document-library/Scientific-guideline/2009/09/WC500003122.pdf (Accessed 21 March 2013).
154. Lewis JH, Mortensen ME, Zweig S, et al. Safety and efficacy of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease. Results of a prospective, randomized, double-blind, placebo-controlled trial. Hepatology. 2007;46(5):1453-63.
155. M'Kada H, Munteanu M, Perazzo H, et al. What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI). Regul Toxicol Pharmacol. 2011;60(3):290-5.
156. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137(1):1-10.
157. Zheng MH, Shi KQ, Fan YC, et al. Upper limits of normal for serum alanine aminotransferase levels in Chinese Han population. PLoS One. 2012;7(9):e43736.
158. Elinav E, Ben-Dov IZ, Ackerman E, et al. Correlation between serum alanine aminotransferase activity and age: an inverted U curve pattern. Am J Gastroenterol. 2005;100(10):2201-4.
159. Dong MH, Bettencourt R, Brenner DA, et al. Serum levels of alanine aminotransferase decrease with age in longitudinal analysis. Clin Gastroenterol Hepatol. 2012;10(3):285-90.
160. Watkins PB, Merz M. Liver safety assessment in clinical drug development: best practices workshop. Boston: Hilton Back Bay Hotel; 2012.
161. Lee WM, Senior JR. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol Pathol. 2005;33(1):155-64.
162. Aithal GP, Rawlins MD, Day CP. Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ. 1999;319(11):1541.
163. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology. 2001;33(1):308-10.
164. Danan G, Benichou C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46(11):1323-30.
165. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs - II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46(11):1331-6.
166. Aithal GP, Rawlins MD, Day CP. Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. J Hepatol. 2000;33(6):949-52.
167. Maria VAJ, Victorino RMM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology. 1997;26(3):664-9.
168. Lucena M, Camargo R, Andrade R, et al. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology. 2001;33(1):123-30.
169. Shapiro M, Lewis JH. Causality assessment of drug-induced liver disease. Promises and pitfalls. Clin Liver Dis. 2007;11(3):477-505.
170. Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89(6):806-15.
171. Blanc S, Leuenberger P, Berger J-P, et al. Judgments of trained observers on adverse drug reactions. Clin Pharmacol Ther. 1979;25(5):493-8.
172. Teschke R, Schulze J. Suspected herbal hepatotoxicity: requirements for appropriate causality assessment by the US Pharmacopeia. Drug Saf. 2012;35(12):1091-7.
173. Lewis JH, Larrey D, Olsson R, et al. Utility of the Roussel Uclaf Causality Assessment Method (RUCAM) to analyze the hepatic findings in a clinical trial program: evaluation of the direct thrombin inhibitor ximelagatran. Int J Clin Pharmacol Ther. 2008;46(7):327-39.
174. Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf Causality Assessment Method. Hepatology. 2010;51(6):2117-26.
175. Fontana RJ, Seeff LB, Andrade RJ, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology. 2010;52(2):737-42.
176. Nathwani RA, Kumar SR, Reynolds TB, et al. Marked elevation in serum transaminases: an atypical presentation of choledocholithiasis. Am J Gastroenterol. 2005;100(2):295-8.
177. Barritt AS 4th, Lee J, Hayashi PH. Detective work in drug-induced liver injury: sometimes it is all about interviewing the right witness. Clin Gastroenterol Hepatol. 2010;8(7):635-7.
178. Hoofnagle JH, Hepatitis E. N Engl J Med. 2012;367(13):1237-44.
179. Dalton HR, Fellows HJ, Stableforth W, et al. The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther. 2007;26(10):1429-35.
180. Davern TJ, Chalasani N, Fontana RJ, et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology. 2011;141(5):1665-72.
181. Chen EY, Baum K, Collins W, et al. Hepatitis E masquerading as drug-induced liver injury. Hepatology. 2012;56(6):2420-3.
182. Watkins PB, Seligman PJ, Pears JS, et al. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology. 2008;48(5):1680-9.
183. Little RJ, D'Agostino R, Cohen ML, et al. The prevention and treatment of missing clinical data in clinical trials. N Engl J Med. 2012;367(14):1355-60.
184. Agarwal VK, McHutchison JG, Hoofnagle JH, for the Drug-induced Liver Injury Network. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol. 2010;8(5):463-70.
185. Haller C, James LP. Adverse drug reactions: moving from chance to science. Clin Pharmacol Ther. 2011;89(6):761-4.
186. Brown EG. Using MedDRA: implications for risk management. Drug Saf. 2004;27(8):591-602.
187. Lee WM. Acute liver failure. Semin Respir Crit Care Med. 2012;33(1):36-45.
188. Allan MC. A primer of drug safety surveillance: an industry perspective. Part III: managing adverse-event data. J Pharm Technol. 1992;8(6):259-73.
189. Tsintis P, La Mache E. CIOMS and ICH initiatives in pharmacovigilance and risk management: overview and implications. Drug Saf. 2004;27(8):509-17.
190. Hammond IW, Gibbs TG, Seifert HA, et al. Database size and power to detect safety signals in pharmacovigilance. Expert Opin Drug Saf. 2007;6(6):713-21.
191. Bate A, Lindquist M, Edwards IR. The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database. Fundam Clin Pharmacol. 2008;22(2):127-40.
192. Giezen TJ, Mantel-Teeuwisse AK, Leufkens HG. Pharmacovigilance of biopharmaceuticals: challenges remain. Drug Saf. 2009;32(10):811-7.
193. Chen M, Vijay V, Shi Q, et al. FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today. 2011;16(15-16):697-703.
194. Johann-Liang R, Wyeth J, Chen M, et al. Pediatric drug surveillance and the Food and Drug Administration's adverse event reporting system: an overview of reports, 2003-2007. Pharmacoepidemiol Drug Saf. 2009;18(1):24-7.
195. Hauben M, Horn S, Reich L. Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions. Drug Saf. 2007;30(2):143-55.
196. Rosati K. Using electronic health information for pharmacovigilance: the promise and the pitfalls. J Health Life Sci Law. 2009;2:173-239.
197. Avorn J. Two centuries of assessing drug risks. N Engl J Med. 2012;367(3):193-7.
198. Brewster W, Gibbs T, Lacroix K, et al. Evolving paradigms in pharmacovigilance. Curr Drug Saf. 2006;1(2):127-34.
199. Almenoff JS, Pattishall EN, Gibbs TG, et al. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther. 2007;82(2):157-66.
200. Wilson AM, Thabane L, Holbrook A. Application of data mining techniques in pharmacovigilance. Br J Clin Pharmacol. 2004;57(2):127-34.
201. Wang HW, Hochberg AM, Pearson RK, et al. An experimental investigation of masking in the US FDA adverse event reporting system database. Drug Saf. 2010;33(12):1117-33.
202. Hauben M, Reich L. Safety related drug-labelling changes: findings from two data mining algorithms. Drug Saf. 2004;27(10):735-44.
203. Manso G, Thole Z, Salgueiro E, et al. Spontaneous reporting of hepatotoxicity associated with antiandrogens: data from the Spanish pharmacovigilance system. Pharmacoepidemiol Drug Saf. 2006;15(4):253-9.
204. Dore DD, DiBello JR, Lapane KL. Telithromycin use and spontaneous reports of hepatotoxicity. Drug Saf. 2007;30(8):697-703.
205. Chen Y, Guo JJ, Healy DP, et al. Risk of hepatotoxicity associated with the use of telithromycin: a signal detection using data mining algorithms. Ann Pharmacother. 2008;42(12):1791-6.
206. Brinker AD, Wassel RT, Lyndly J, et al. Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology. 2009;49(1):250-7.
207. Lawrenson RA, Seaman HE, Sundstrom A, et al. Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data. Drug Saf. 2000;23(4):333-49.
208. Safer DJ, Zito JM, Gardner JE. Pemoline hepatotoxicity and postmarketing surveillance. J Am Acad Child Adolesc Psychiatry. 2001;40(6):622-9.
209. Etwel FA, Rieder MJ, Bend JR, et al. A surveillance method for the early identification of idiosyncratic adverse drug reactions. Drug Saf. 2008;31(2):169-80.
210. Conforti A, Magro L, Moretti U, et al. Fluvastatin and hepatic reactions: a signal from spontaneous reporting in Italy. Drug Saf. 2006;29(12):1163-72.
211. Bezabeh S, Flowers CM, Kortepeter C, et al. Clinically significant liver injury in patients treated with natalizumab. Aliment Pharmacol Ther. 2010;31(9):1028-35.
212. Hauben M, Vegni F, Reich L, et al. Postmarketing hepatic adverse event experience with PEGylated/non-PEGylated drugs: a disproportionality analysis. Eur J Gastroenterol Hepatol. 2007;19(11):934-41.
213. Stromborn I, Wernicke JF, Seeger J, et al. Hepatic effects of duloxetine - III: analysis of hepatic events using external data sources. Curr Drug Saf. 2008;3(2):154-62.
214. Alsheikh-Ali AA, Karas RH. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system). Am J Cardiol. 2007;99(3):379-81.
215. Thiessard F, Roux E, Miremont-Salame G, et al. Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001). Drug Saf. 2005;28(8):731-40.
216. Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med. 2007;167(16):1752-9.
217. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009;32(1):19-31.
218. Shetty KD, Dalal SR. Using information mining of the medical literature to improve drug safety. J Am Med Inf Assoc. 2011;18(5):668-74.
219. Alves C, Batel-Marques F, Macedo AF. Data sources on drug safety evaluation: a review of recent published meta-analyses. Pharmacoepidemiol Drug Saf. 2012;21(1):21-33.
220. Jinjuvadia K, Kwan W, Fontana RJ. Searching for a needle in a hatstack: use of ICD-9-CM codes in drug-induced liver injury. Am J Gastroenterol. 2007;102(11):2437-43.
221. Sgro C, Clinard F, Quazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36(2):451-5.
222. Hammond IW, Rich DS, Gibbs TG. Effect of consumer reporting on signal detection: using disproportionality analysis. Expert Opin Drug Saf. 2007;6(6):705-12.
223. Basch E, Jia X, Heller G, et al. Adverse symptom reporting by patients versus clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009;101(23):1624-32.
224. Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med. 2010;362(10):865-9.
225. Anderson C, Krska J, Murphy E, et al. The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective. Br J Clin Pharmacol. 2011;72(5):806-22.
226. Avery AJ, Anderson C, Bond CM, et al. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. 2011;15:1-234.
227. Pushkin R, Frassetto L, Tsourounis C, et al. Improving the reporting of adverse drug reactions in the hospital setting. Postgrad Med. 2010;122(6):154-64.
228. Gavaza P, Brown CM, Lawson KA, et al. Influence of attitudes on pharmacists' intention to report serious adverse drug events to the Food and Drug Administration. Br J Clin Pharmacol. 2011;72(1):143-52.
229. Hasford J, Goettler M, Munter KH, et al. Physicians' knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions. J Clin Epidemiol. 2002;55(9):945-50.
230. Kaufman MB, Stoukides CA, Campbell NA. Physicians' liability for adverse drug reactions. South Med J. 1994;87(8):780-4.
231. Kesselheim AS, Avorn J. The role of litigation in defining drug risks. JAMA. 2007;297(3):308-11.
232. Adebayo D, Mookerjee RP, Jalan R. Mechanistic biomarkers in acute liver injury: are we there yet? J Hepatol. 2012;56(5):1003-5.
233. Watkins PB. Biomarkers for the diagnosis and management of drug-induced liver injury. Semin Liver Dis. 2009;29(4):393-9.
234. Collins BC, Miller CA, Sposny A, et al. Development of a pharmaceutical hepatotoxicity biomarker panel using a discovery to targeted proteomics approach. Mol Cell Proteomics. 2012;11(8):394-410.
235. Ozer J, Ratner M, Shaw M, et al. The current state of serum biomarkers of hepatotoxicity. Toxicology. 2008;245(3):194-205.
236. Ozer JS, Chetty R, Kenna G, et al. Recommendations to qualify biomarker candidates of drug-induced liver injury. Biomark Med. 2010;4(3):475-83.
237. Bell LN, Vuppalanchi R, Watkins PB, et al. Serum proteomic profiling in patients with drug-induced liver injury. Aliment Pharmacol Ther. 2012;35(5):600-12.
238. Abacavir. LiverTox Drug record. http://livertox.nih.gov/Abacavir.htm (Accessed 22 March 2013).
239. Hughes DA, Vilar FJ, Ward CC, et al. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics. 2004;14(6):335-42.
240. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568-79.
241. Lucena M, Molokhia M, Shen Y. Susceptibility to amoxicillin-clavulanate- induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology. 2011;141(1):338-47.
242. Krawczyk M, Mullenbach R, Weber S, et al. Genome-wide association studies and genetic risk assessment of liver diseases. Nat Rev Gastroenterol Hepatol. 2010;7:669-80.
243. Liss G, Rattan S, Lewis JH. Predicting and preventing acute drug-induced liver injury: what's new in 2010. Expert Opin Drug Metab Toxicol. 2010;6(9):1-15.
244. Stine JG, Lewis JH. Drug-induced liver injury: a summary of recent advances. Expert Opin Drug metab Toxicol. 2011;7(7):875-90.
245. Pirmohamed M, Aithal GP, Behr E, et al. The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions. Clin Pharmacol Ther. 2011;89(6):784-8.
246. Slutsky AS, Lavery JV. Data safety monitoring boards. N Engl J Med. 2004;350(11):1143-6.
247. Tereskerz PM, Guterbock TM, Kermer DA, et al. An opinion and practice survey on the structure and management of data and safety monitoring boards. Acc Res. 2011;18(1):1-30.
248. Lewis JH. Risk-benefit assessment of new drugs: perspectives of a former FDA Advisory Committee member. Drug Inf J. 1993;27:1037-49.
249. Nicholson SC, Peterson J, Yektashenas B. Risk evaluation and mitigation strategies (REMS): educating the prescriber. Drug Saf. 2012;35(1):91-104.